Looks like you’re on the UK site. Choose another location to see content specific to your location
Merck Sharp and Dohme presents Keytruda data at 2018 ASCO GI Symposium
Merck Sharp and Dohme has presented new clinical data on Keytruda at this year's American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
During the conference in San Francisco, the company announced findings from the registrational phase II KEYNOTE-224 trial investigating the use of this anti-PD-1 therapy in patients with advanced hepatocellular carcinoma, the most common type of liver cancer.
Among patients who were previously treated with systemic therapy, results showed an overall response rate of 16.3 percent with Keytruda as a monotherapy, with six-month overall survival and progression-free survival rates shown to be strong.
Dr Roger Dansey, senior vice-president and head of oncology late-stage development at Merck Research Laboratories, said: "The findings from this study demonstrate the potential of Keytruda in patients with advanced HCC following prior systemic therapy and support the advancement of our clinical development programme in this cancer type."
In total, the company has conducted more than 650 trials studying Keytruda across a wide variety of cancers and treatment settings, including multiple gastrointestinal disorders such as hepatocellular carcinoma and gastroesophageal cancer.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard